PRLog - Jul. 19, 2011 - NEEDHAM, Mass. -- NEEDHAM, MASS. – Cambridge Healthtech Institute’s Insight Pharma Reports announces the Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances Report, Authored by Ken Rubenstein, PhD.
This report focuses on current and innovative NGS technologies, services and markets to answer such questions as;
•Which early NGS market entrants have been continually improving and updating their original systems?
•Who has introduced new scaled-down instruments to broaden the market?
•What Generation 2.5 systems featuring new detection technologies and single-molecule sequencing are now on the market?
•When will third generation of instruments led by nanopore technologies be entering the commercial feasibility stage?
•Why upstream sample handling is undergoing continual technological innovation?
•Which informatics providers are moving rapidly toward fully integrated systems to provide the rapid generation of actionable biological information?
Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances describes these innovations and analyzes their impact on this extremely dynamic technology and market sector. We report on the:
•NGS systems on the market and those on the horizon
•Possible game changing innovations still in development
•NGS market dynamics for instruments and services
•Results of an Insight Pharma Reports’ user market survey
•Interviews with six experts on diverse aspects of NGS
•Analysis on how the field will likely develop over the next several years.
Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances updates the product offerings from Roche/454, Illumina, Life Technologies (Ion Torrent), Complete Genomics (CGI), Helicos, Pacific Biosciences (PacBio). As well as NGS upstream sample preparation and downstream informatics, aspects of NGS that have developed into substantial and fast-growing markets of their own. Companies in the informatics space covered in this report include Geospiza, Accelrys, GenoLogics, CLC bio, GenomeQuest, Partek, and DNAStar and Ingenuity Systems.
Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances looks at a number of new product and technology candidates in varying stages of development. As the report highlights, some candidates are mainly extensions of current technologies, while others represent something very different.
Large companies have entered the new technology race such as General Electric, IBM as well as Life Technologies with its Starlight system. Many small entrepreneurial companies are also covered in this report including GnuBio’s with its microreactors, Halcyon Molecular and ZS Genetics’ use of scanning transmission electron microscopy, Intelligent Bio-Systems’
Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances investigates the market dynamics where Illumina, Life Technologies, and Roche currently dominate a sequencer market now estimated to exceed $1 billion per year. It’s a market where companies are making continual advances in cost and performance at a pace exceeding that associated with semiconductor technology, where market adoption, application diversity, and implications for life science research continue to advance.
•Learn from this report the answers to such questions as:
•Why is Illumina the clear market leader, accounting for about 60% of revenues?
•Who are the key players in the NGS services market for now?
•What’s attractive about Pacific Biosciences’
•What will be the impact of low-cost systems?
•Will the market expand into clinical diagnostic applications?
For more information and to purchase this Insight Pharma Report, visit: http://www.insightpharmareports.com
About Insight Pharma Reports
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute. http://insightpharmareports.com
# # #
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets.